'Gene discovery may help treat aggressive breast cancer'


Scientists say they have identified a master switch that appears to control the dynamic behavior of tumor cells which makes some aggressive cancers so difficult to treat.

The finding, published in the journal Cancer Cell, could open new avenues for diagnosing and treating aggressive breast cancer as well as other types of intractable cancers.

The gene Sox10 directly controls the growth and invasion of a significant fraction of hard-to-treat triple-negative breast cancers, said researchers from Salk Institute in the US.

They discovered that aggressive breast cancers return to a flexible, earlier state found in fetal breast tissue.

This cellular reprogramming may be the key to cancer's ability to form new cell types, evolve drug resistance and metastasize to other locations in the body, researchers said.

"Two things that make triple-negative breast cancers so hard to treat are their heterogeneity -- they have many different cell types within a single tumor -- and their ability to move around and colonize new areas, the process of metastasis," said Geoffrey Wahl, a

professor at Salk Institute.

"It is what you could call the imprecision in precision medicine, in the sense that we might target one type of cell, but there are other cells within the tumor that can change to become drug-resistant, analogous to how a chameleon changes colors to evade predators," Wahl said.

In order to develop from a single cell into a complete organism such as a mouse or human, embryonic and fetal cells have the ability to divide rapidly, move throughout the body and change into multiple different cell types --properties known as "plasticity."

However, adult cells turn off this plasticity, which, for reasons that are not fully understood, can get reawakened and turn cells cancerous.

(This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.)

Give Feedback

Use this form for editorial or site feedback. We usually reply within 2 to 3 working days.

By submitting, you agree that we may use your email address to respond.